Related Experiment Videos
Beta-blocker underuse in secondary prevention of myocardial infarction
Matthew J Everly1, Pamela C Heaton, Robert J Cluxton
1Division of Pharmacy Practice, College of Pharmacy, University of Cincinnati, Cincinnati, OH, USA.
Insights
Beta-blockers significantly reduce mortality and reinfarction after myocardial infarction (MI). Despite proven benefits, underuse persists in certain patient groups due to perceived risks, but careful management can mitigate these concerns.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are crucial for secondary prevention after myocardial infarction (MI).
- Clinician reluctance to prescribe beta-blockers in specific populations, particularly those with comorbidities, is a recognized issue.
- Understanding the balance between beta-blocker benefits and risks in diverse patient groups is essential for optimal post-MI care.
Purpose of the Study:
- To review the established clinical benefits of beta-blockers for secondary prevention following MI.
- To investigate the reasons behind the underuse of beta-blockers in specific patient populations.
- To provide guidance on the safe and effective use of beta-blockers in patients with comorbidities.
Main Methods:
- Systematic literature search of MEDLINE (1966-2002) and hand search of references.
- Inclusion of English-language human studies reporting on beta-blocker use and secondary prevention of MI.
- Analysis of studies examining associations between beta-blocker underuse and patient characteristics or comorbidities.
Main Results:
- Beta-blocker use after MI is associated with significant reductions in mortality (19-48%) and reinfarction rates (up to 28%).
- Underuse is prevalent in older patients and those with diabetes, heart failure, COPD, asthma, and peripheral arterial disease.
- Perceived adverse events contribute to underuse, though careful dosing and selection (e.g., cardioselective agents) can manage risks in most comorbid conditions.
Conclusions:
- The substantial cardiovascular benefits of beta-blockers in secondary MI prevention outweigh the associated risks.
- Careful titration and selection of beta-blockers allow safe use in most patients with comorbidities, including the elderly, diabetics, and those with heart failure or respiratory conditions.
- Addressing clinician concerns and patient-specific factors is key to improving beta-blocker utilization for secondary MI prevention.
Objective:
To review the clinical benefits of beta-blockers as secondary prevention following a myocardial infarction (MI) and to address the reasons that clinicians are reluctant to use beta-blockers in specific patient populations.
Data Sources:
MEDLINE was searched for articles published from January 1966 to October 2002. Relevant studies were identified by systematic searches of the literature for all reported studies of associations between beta-blocker underuse and secondary prevention of MI. Additional studies were identified by a hand search of references of original or review articles.
Study Selection And Data Extraction:
English-language human studies were selected and analyzed.
Data Synthesis:
Associations were observed in studies of beta-blocker use as secondary prevention of MI. A lower rate of beta-blocker treatment occurred in older patients and in patients with comorbid conditions such as diabetes, heart failure, chronic obstructive pulmonary disease, asthma, and peripheral arterial disease. In addition, underuse was attributed to the perception of high rates of adverse events associated with beta-blockers. beta-Blocker use as secondary prevention of an MI can lead to a 19-48% decrease in mortality and up to a 28% decrease in reinfarction rates. Nonetheless, beta-blockers are significantly underused in many patient populations due to concomitant disease states. Due to their normal physiologic deterioration, the elderly are at an increased risk of low cardiac output and bradycardia when given a beta-blocker; therefore, they should be started on a low dose that is then slowly titrated. In diabetic patients, beta-blockers can impair glucose control leading to hypoglycemia; therefore, post-MI diabetic patients must routinely monitor their blood glucose levels. In patients with decompensated heart failure, beta-blocker use can lead to further cardiac depression, but lower oral starting doses with slow titration can reduce this risk. beta-Blockers can induce bronchospasm in patients with chronic obstructive pulmonary disease or asthma, but cardioselective beta-blockers and appropriate use of medications such as albuterol can minimize these effects. Finally, in patients with peripheral arterial disease, with the exception of hypertensive patients with Reynaud's phenomenon, beta-blockers can be used safely. The only absolute contraindications to beta-blockers are severe bradycardia, preexisting sick sinus syndrome, second- and third-degree atrioventricular block, severe left ventricular dysfunction, active peripheral vascular disease with rest ischemia, or reactive airway disease so severe that airway support is required.
Conclusions:
Overall, the cardiovascular benefits of beta-blockers as secondary prevention of MI significantly outweigh the risks associated with their use.
Related Concept Videos
01:22Heart Failure Drugs: β-Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:28Antihypertensive Drugs: Types of β-Blockers
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System